Technical Analysis for TCRX - TScan Therapeutics, Inc.

Grade Last Price % Change Price Change
F 4.12 -2.14% -0.09
TCRX closed down 2.14 percent on Wednesday, November 20, 2024, on 74 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -2.14%
Wide Bands Range Expansion -2.14%
Oversold Stochastic Weakness -2.14%
Lower Bollinger Band Walk Weakness -1.90%
Stochastic Reached Oversold Weakness -1.90%
Wide Bands Range Expansion -1.90%
Down 3 Days in a Row Weakness -1.90%

   Recent Intraday Alerts

Alert Time
Lower Bollinger Band Support about 17 hours ago
Down 3% about 17 hours ago
Fell Below Previous Day's Low about 17 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
Possible NR7 about 17 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer

Is TCRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.69
52 Week Low 4.03
Average Volume 224,625
200-Day Moving Average 6.60
50-Day Moving Average 5.21
20-Day Moving Average 4.98
10-Day Moving Average 4.99
Average True Range 0.35
RSI (14) 31.03
ADX 23.0
+DI 18.40
-DI 34.22
Chandelier Exit (Long, 3 ATRs) 5.18
Chandelier Exit (Short, 3 ATRs) 5.08
Upper Bollinger Bands 6.04
Lower Bollinger Band 3.92
Percent B (%b) 0.09
BandWidth 42.43
MACD Line -0.24
MACD Signal Line -0.10
MACD Histogram -0.1331
Fundamentals Value
Market Cap 179.42 Million
Num Shares 43.5 Million
EPS -2.02
Price-to-Earnings (P/E) Ratio -2.04
Price-to-Sales 16.41
Price-to-Book 1.70
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.42
Resistance 3 (R3) 4.42 4.33 4.37
Resistance 2 (R2) 4.33 4.25 4.33 4.35
Resistance 1 (R1) 4.22 4.20 4.18 4.22 4.34
Pivot Point 4.13 4.13 4.10 4.13 4.13
Support 1 (S1) 4.02 4.05 3.98 4.02 3.90
Support 2 (S2) 3.93 4.00 3.93 3.89
Support 3 (S3) 3.82 3.93 3.87
Support 4 (S4) 3.82